SV Inflections Biotech Inflection Investing

Biotech investments
driven by the accurate prediction of clinical trial success rates


We thrive to accurately predict clinical trial results and the resulting changes in share price of publicly traded biotechnology companies. Wrapped in a proprietary investment strategy, we aim to generate returns for investors with low market correlation, while at the same time advancing scientific breakthroughs for patients.


Jonathan & Graham – scientists at heart, drug developers by training

We are specialists in fundamental analysis, especially in the scientific evaluation of drugs. We have a strong scientific background and many years of experience working hand-in-hand with pharma – developing drugs and supervising M&A activities. Together with our team, we have perfectionated the prediction of the clinical trial readouts over the years.


Publicly traded biotechnology companies of which the SV Inflections FCP-RAIF held shares during the announcement of key clinical data readouts. In all cases, urgently needed novel therapies advanced a considerable step towards alleviating the suffering of patients. *

agios logo
albireo logo
argenx logo
bioxcel logo
cabaletta logo
cardiff logo
celldex logo
equillium logo
forma logo
gamida cell logo
kastavista logo
kodiak logo
kastavista logo
larimar logo
morphic logo
novavax logo
ocuphire logo
pliant logo
protagonist logo
rhythm logo
sio logo
tg logo
tracon logo
travere logo
valneva logo

* The Content of these investments in the past is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.

Do you have questions?

Can we provide more information? Please don’t hesitate to get in touch.

  • Address

    SV Inflections GmbH & Co. KG
    Dr. Jonathan Vonnemann
    Dr. Graham Scholefield
    Lennéstr. 9 | 10785 Berlin